GSK2643943AMRTX1133pancreatic ductal adenocarcinoma (PDAC)
…-1 (anti-PD-1). In preclinical PDAC models, triple therapy with GSK2643943A, MRTX1133 and anti-PD-1 elicited a robust therapeutic response …
4articles mentioning drugs
9drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: MRTX1133 ×
MRTX1133
This drug is selected. Its supporting articles are shown below.
Articles mentioning MRTX1133
4 articles · page 1 of 1AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
MRTX1133CLDN18.2O-GlcNAcylated CLDN18.2KPC micepancreatic ductal adenocarcinomagastric and gastro-oesophageal junction cancersPDAC
…on and suppresses tumour progression. Therapeutically, low-dose MRTX1133 (KRASG12D inhibitor) reduces O-GlcNAcylation and synergises wit…
ARC39MRTX1133pancreatic ductal adenocarcinomacancerPDAC
…ependent sphingolipid metabolism. Notably, the SMPD1 inhibitor (ARC39) potently synergised with the KrasG12D inhibitor (MRTX1133).Con…